Kyto Technology and Life Science, Inc. (KBPH)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Kyto Technology and Life Science, Inc. (KBPH) trades at $1.00 with AI Score 38/100 (Grade D). Kyto Technology and Life Science, Inc. is a venture capital firm that focuses on early-stage technology and life science companies. Market cap: $13.29M, Sector: Financial services.
Price live · AI analysis from Mar 15, 2026Analyst Coverage for KBPH: KBPH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates KBPH against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
KBPH: 1/1 perspectives are bearish.
How is this calculated? →Kyto Technology and Life Science, Inc. (KBPH) Financial Services Profile
Kyto Technology and Life Science, Inc. is a venture capital firm specializing in early-stage technology and life science investments, operating primarily in the United States, Canada, and Israel. The firm strategically employs secured convertible debt and preferred share acquisitions, distinguishing itself by not leading financing transactions and maintaining a focused geographic investment strategy.
What Is the Investment Thesis for KBPH?
Kyto Technology and Life Science, Inc. presents a focused investment approach within the venture capital landscape, targeting early-stage technology and life science companies. With a market capitalization of $13.29M and a P/E ratio of 15.9, the company's valuation reflects its niche investment strategy. Growth catalysts include strategic investments in promising startups and favorable conversion terms on secured convertible debt. However, potential risks include the illiquidity of OTC markets and the high-risk nature of early-stage ventures. The company's beta of 0.02 indicates low volatility compared to the broader market.
Based on FMP financials and quantitative analysis
KBPH Key Highlights
- Kyto Technology and Life Science, Inc. focuses on early-stage investments in technology and life science companies.
- The firm invests through secured convertible debt and direct preferred share purchases.
- Kyto allocates 50% of its investments to companies in the United States and the remaining 50% to Canada and Israel.
- The company operates with a small team, managed by CEO Paul M. Russo.
- Kyto's market capitalization is $0.01 billion, with a P/E ratio of 15.9.
Who Are KBPH's Competitors?
KBPH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AVFCF ADVFN Plc | $0.27 | +0.00% | $12.50M | 45 |
| ECGR Bellatora Inc. | $0.80 | +17.65% | $13.39M | 49 |
| MCPH Midland Capital Holdings Corp. | $30.00 | -7.69% | $11.18M | 55 |
| NACQF NextPoint Financial Inc. | $0.22 | -75.82% | $14.12M | 44 |
| NXDT NexPoint Diversified Real Estate Trust | $5.53 | +3.08% | $285.77M | 73 |
| GENB Generate Biomedicines, Inc. | $17.03 | -2.18% | $2.18B | 72 |
| SII Sprott Inc. | $118.11 | +2.72% | $3.05B | 71 |
| IDDTF AB Industrivärden (publ) | $59.80 | +74.60% | $25.83B | 70 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are KBPH's Key Strengths?
- Specialized focus on technology and life science sectors.
- Use of secured convertible debt for downside protection.
- Geographic diversification across the United States, Canada, and Israel.
- Experienced management team.
What Are KBPH's Weaknesses?
- Small market capitalization.
- Limited number of employees.
- Dependence on the success of early-stage investments.
- Illiquidity of OTC market.
What Could Drive KBPH Stock Higher?
- Potential for successful exits from portfolio companies through IPOs or acquisitions.
- Strategic investments in emerging technology sectors.
- Favorable conversion terms on secured convertible debt.
What Are the Key Risks for KBPH?
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Economic downturn impacting venture capital funding.
- Failure of portfolio companies.
- Illiquidity of OTC market.
- Limited financial disclosure due to OTC Other tier status.
- Increased competition from other venture capital firms.
What Are the Growth Opportunities for KBPH?
- Expansion into Emerging Technology Sectors: Kyto can capitalize on emerging technology sectors such as artificial intelligence, blockchain, and renewable energy. These sectors are experiencing rapid growth and offer significant investment opportunities. By strategically allocating capital to startups in these areas, Kyto can enhance its portfolio and generate substantial returns. The global AI market, for example, is projected to reach trillions of dollars by 2030, presenting a vast landscape for potential investments.
- Strategic Partnerships with Research Institutions: Collaborating with universities and research institutions can provide Kyto with access to cutting-edge technologies and promising startups. These partnerships can facilitate early-stage investments in companies with strong intellectual property and innovative solutions. By establishing relationships with leading research institutions, Kyto can gain a competitive advantage in identifying and securing investment opportunities.
- Geographic Expansion within North America: While Kyto already invests in the United States and Canada, expanding its presence within North America can unlock new opportunities. Targeting specific regions with strong technology and life science ecosystems, such as Silicon Valley, Boston, and Toronto, can provide access to a larger pool of potential investments. This expansion can be achieved through strategic partnerships, new office locations, or targeted marketing efforts.
- Focus on Sustainable and Socially Responsible Investments: Increasing demand for sustainable and socially responsible investments presents a growth opportunity for Kyto. By prioritizing investments in companies that address environmental and social challenges, Kyto can attract a growing segment of investors who are seeking both financial returns and positive impact. This strategy can enhance Kyto's reputation and attract capital from impact-focused investors.
- Leveraging Convertible Debt for Downside Protection: Kyto's use of secured convertible debt provides downside protection while allowing participation in the upside potential of early-stage companies. This strategy can be particularly effective in volatile markets, as it provides a cushion against potential losses. By strategically utilizing convertible debt, Kyto can mitigate risk and enhance its overall investment performance.
What Opportunities Does KBPH Have?
- Expansion into emerging technology sectors.
- Strategic partnerships with research institutions.
- Geographic expansion within North America.
- Focus on sustainable and socially responsible investments.
What Threats Does KBPH Face?
- Economic downturn impacting venture capital funding.
- Increased competition from other venture capital firms.
- Regulatory changes affecting the technology and life science sectors.
- Failure of portfolio companies.
What Are KBPH's Competitive Advantages?
- Specialized focus on technology and life science sectors.
- Strategic use of secured convertible debt for downside protection.
- Geographic diversification across the United States, Canada, and Israel.
What Does KBPH Do?
Founded in 1999, Kyto Technology and Life Science, Inc., formerly known as Kyto BioPharma, Inc., is a venture capital firm headquartered in Los Altos Hills, California, with an additional office in Scotts Valley. The firm specializes in providing capital to startups and early-stage companies within the technology and life science sectors. Kyto's investment strategy centers on secured convertible debt, which pays interest and offers a discount upon conversion to preferred shares, and direct investments into preferred shares. Kyto Technology and Life Science, Inc. differentiates itself by not leading financing transactions, instead participating as a strategic investor. The firm strategically allocates its investments, with 50% directed towards companies in the United States and the remaining 50% split between Canada and Israel. This geographic focus allows Kyto to tap into diverse innovation ecosystems while maintaining a concentrated portfolio. The company changed its name in April 2018 to reflect its broader focus on technology and life science investments.
What Products and Services Does KBPH Offer?
- Invests in startups and early-stage companies.
- Focuses on technology and life science sectors.
- Provides capital through secured convertible debt.
- Makes direct investments into preferred shares.
- Does not lead financing transactions.
- Allocates investments between the United States, Canada, and Israel.
How Does KBPH Make Money?
- Generates returns through capital appreciation of equity investments.
- Earns interest income from secured convertible debt.
- Benefits from discounts upon conversion of debt to preferred shares.
What Industry Does KBPH Operate In?
Kyto Technology and Life Science, Inc. operates within the competitive asset management industry, specifically focusing on venture capital investments in technology and life science startups. The venture capital market is characterized by high growth potential but also significant risk. Kyto competes with other venture capital firms such as AVFCF, CUII, ECGR, MCPH, and NACQF, each with varying investment strategies and geographic focuses. The industry is influenced by technological advancements, regulatory changes, and macroeconomic conditions, all of which impact the availability of capital and the valuation of early-stage companies.
Who Are KBPH's Key Customers?
- Startups and early-stage companies in the technology sector.
- Startups and early-stage companies in the life science sector.
- Companies seeking venture capital funding.
Net buyingInsider Activity
The most recent 12 insider filings for Kyto Technology and Life Science, Inc. break down as 3 sales and 9 purchases. On net that is roughly 9.1M shares acquired (about $823K) — insiders putting money in tends to read as conviction.
KBPH Valuation & Market Position
With a $13.29M market cap, Kyto Technology and Life Science, Inc. sits in the micro-cap segment of the market. Relative to its peer group, KBPH's quantitative score of 38/100 is below the peer average of 53/100.
ROE 9%Key Financial Metrics
Return on equity for Kyto Technology and Life Science, Inc. stands at 8.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 5.1%, showing how much profit it generates from its asset base. KBPH trades at a trailing price-to-earnings ratio of 15.94, below the Financial Services sector average of ~18x. Its free cash flow yield is -18.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.57 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 6.3%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 3/9Financial Health
Kyto Technology and Life Science, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 51.00 places it in the safe zone, indicating low near-term bankruptcy risk.
Company Profile
Kyto Technology and Life Science, Inc. operates in the Asset Management industry within the Financial Services sector. It is headquartered in Los Altos Hills, US. The company is led by CEO Paul M. Russo. KBPH has traded publicly since 2007.
KBPH Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that leaders believe in upcoming advancements.
- Community sentiment has shifted positively, with discussions highlighting potential breakthroughs in their biotech pipeline.
- Increased media coverage has sparked interest among retail investors, boosting overall market perception of the company.
- Recent partnerships and collaborations have positioned the company advantageously within the competitive biotech landscape.
Bear Case
- Concerns about regulatory hurdles have emerged, casting doubt on the timeline for product approvals and market entry.
- Social sentiment has shown some skepticism, with discussions reflecting worries about the scalability of their technologies.
- Market perception remains cautious due to the volatility seen in the biotech sector, particularly among smaller firms like Kyto.
- Recent earnings reports have raised questions about the company's financial health, leading to bearish views from some analysts.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
KBPH Latest News
No recent news available for KBPH.
KBPH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for KBPH.
Price Targets
Wall Street price target analysis for KBPH.
KBPH MoonshotScore
What does this score mean?
The MoonshotScore rates KBPH's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Paul M. Russo
Managing Director
Paul M. Russo serves as the Managing Director of Kyto Technology and Life Science, Inc. His background encompasses extensive experience in venture capital and early-stage company development. He is responsible for overseeing the firm's investment strategy, portfolio management, and overall operations. His leadership is pivotal in guiding Kyto's investments in technology and life science companies across the United States, Canada, and Israel.
Track Record: Under Paul M. Russo's leadership, Kyto Technology and Life Science, Inc. has focused on strategic investments in early-stage companies, utilizing secured convertible debt and direct preferred share purchases. He has overseen the firm's geographic diversification and its focus on technology and life science sectors. His decisions have shaped Kyto's investment portfolio and its approach to venture capital.
KBPH OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Kyto Technology and Life Science, Inc. may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies on this tier may have limited financial disclosure and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier is often associated with higher risk and greater potential for volatility due to the limited information available to investors.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure due to OTC Other tier status.
- Higher price volatility due to lower trading volumes.
- Wider bid-ask spreads increasing transaction costs.
- Potential for delisting or suspension of trading.
- Increased risk of fraud or manipulation.
- Verify the company's financial statements and disclosures.
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's capital structure and debt levels.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Understand the risks associated with OTC investments.
- Company has been in operation since 1999.
- Focuses on venture capital investments in technology and life science sectors.
- Investments are split between the United States, Canada, and Israel.
- Company has a physical presence with offices in California.
Kyto Technology and Life Science, Inc. Financial Services Stock: Key Questions Answered
What does Kyto Technology and Life Science, Inc. do?
Kyto Technology and Life Science, Inc. is a venture capital firm that invests in startups and early-stage companies, primarily in the technology and life science sectors. The firm provides capital through secured convertible debt and direct investments into preferred shares. Kyto focuses on companies located in the United States, Canada, and Israel, and it differentiates itself by not leading financing transactions. The company aims to generate returns through capital appreciation and interest income from its investments.
What are the main risks for KBPH?
The main risks for Kyto Technology and Life Science, Inc. include the inherent risks associated with investing in early-stage companies, such as the potential for failure and the illiquidity of investments. As an OTC-listed company, KBPH faces additional risks related to limited financial disclosure, lower trading volumes, and wider bid-ask spreads. Economic downturns and increased competition in the venture capital market could also negatively impact the company's performance. Investors should carefully consider these risks before investing in KBPH.
How does Kyto Technology and Life Science, Inc. generate revenue?
Kyto Technology and Life Science, Inc. generates revenue primarily through two main avenues: capital appreciation from its equity investments and interest income from secured convertible debt. When the early-stage companies in which Kyto invests succeed and increase in value, Kyto benefits from the increased value of its equity holdings. Additionally, the secured convertible debt held by Kyto generates interest income, providing a steady stream of revenue. The firm also benefits from discounts upon conversion of debt to preferred shares, further enhancing its returns.
What regulatory challenges does Kyto Technology and Life Science, Inc. face?
As a venture capital firm, Kyto Technology and Life Science, Inc. faces regulatory challenges related to securities laws and investment regulations. The firm must comply with regulations governing the offer and sale of securities, as well as regulations related to investment management and advisory activities. These regulations aim to protect investors and ensure fair and transparent markets. Compliance with these regulations requires ongoing monitoring and adherence to legal and ethical standards, which can incur costs and require specialized expertise.
What are the key factors to evaluate for KBPH?
Kyto Technology and Life Science, Inc. (KBPH) holds an AI score of 38/100 (low). P/E: 15.9x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does KBPH data refresh on this page?
KBPH prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven KBPH's recent stock price performance?
Kyto Technology and Life Science, Inc. (KBPH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on technology and life science sectors. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider KBPH overvalued or undervalued right now?
Kyto Technology and Life Science, Inc. (KBPH) trades at 15.9x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC market data may have limited reliability.
- AI analysis pending for KBPH, limiting available insights.